Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

PURPOSE: Intratumoral oncolytic virotherapy may overcome anti–PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot study investigated ONCOS-102 (oncolytic adenovirus expressing GM-CSF) plus anti–programmed cell death protein 1 (PD)-1 therapy in anti–...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoushtari, Alexander N., Olszanski, Anthony J., Nyakas, Marta, Hornyak, Thomas J., Wolchok, Jedd D., Levitsky, Victor, Kuryk, Lukasz, Hansen, Thomas B., Jäderberg, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811163/
https://www.ncbi.nlm.nih.gov/pubmed/36112545
http://dx.doi.org/10.1158/1078-0432.CCR-22-2046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811163/
https://www.ncbi.nlm.nih.gov/pubmed/36112545
http://dx.doi.org/10.1158/1078-0432.CCR-22-2046

Ejemplares similares